KALA - Kala Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.06
+0.05 (+1.00%)
As of 9:50AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close5.01
Open5.01
Bid4.9700 x 1000
Ask5.0700 x 800
Day's Range5.00 - 5.10
52 Week Range4.96 - 20.17
Volume12,574
Avg. Volume351,287
Market Cap171.006M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.6160
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.20
Trade prices are not sourced from all markets
  • Business Wire25 days ago

    Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Kala Pharmaceuticals, Inc. (KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 31,000 shares of Kala Pharmaceuticals common stock to nine new employees.

  • Associated Presslast month

    Kala Pharma: 3Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 63 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Business Wirelast month

    Kala Pharmaceuticals Reports Third Quarter 2018 Financial Results

    – INVELTYS™ Launch on Track for Early 2019 –

  • Business Wirelast month

    Kala Pharmaceuticals to Present at the Jefferies 2018 London Healthcare Conference

    Kala Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle Drug Delivery Technology, today announced that it will present at the Jefferies 2018 London Healthcare Conference in London, U.K..

  • Business Wire2 months ago

    Kala Pharmaceuticals Appoints Steven Zhang as Vice President of Medical Affairs

    Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, today announced the appointment of Steven Zhang, M.D., Ph.D., as Vice President of Medical Affairs. “Steven brings a tremendous depth of experience leading medical activities for both clinical stage and commercial ophthalmic products.

  • GlobeNewswire2 months ago

    New Research Coverage Highlights Vmware, Kala Pharmaceuticals, El Pollo Loco, Integer, AAC, and Vectren — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Oct. 24, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire2 months ago

    Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

    Kala Pharmaceuticals, Inc. (KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 48,000 shares of Kala Pharmaceuticals common stock to seven new employees.

  • Business Wire2 months ago

    Kala Pharmaceuticals to Present at the 2018 American Academy of Ophthalmology (AAO) Annual Meeting and at the Ophthalmology Innovation Summit at AAO

    Kala Pharmaceuticals, Inc. , today announced that it will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology meeting taking place on October 25, 2018.

  • Business Wire2 months ago

    Kala Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for KPI-121 0.25% for Dry Eye Disease

    Kala Pharmaceuticals, Inc. (Kala) (KALA), today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for KPI-121 0.25%, a topical product candidate which, if approved, could be the first FDA-approved product for the temporary relief of signs and symptoms of dry eye disease. There are an estimated 33 million patients with dry eye disease in the U.S. and Kala’s market research indicates that approximately 90% of these patients have flares associated with their dry eye disease. KPI-121 0.25% utilizes Kala’s AMPPLIFYTM mucus-penetrating particle (MPP) Drug Delivery Technology, which are selectively-sized nanoparticles with proprietary coatings that significantly enhance drug penetration and distribution in ocular tissues.

  • Business Wire2 months ago

    Kala Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares

    Kala Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle technology, announced today that the underwriters of its previously announced public offering have exercised in full their option to purchase an additional 1,125,000 shares of common stock at the public offering price of $8.25 per ...

  • Kala Pharmaceuticals (KALA) Catches Eye: Stock Jumps 7.4%
    Zacks2 months ago

    Kala Pharmaceuticals (KALA) Catches Eye: Stock Jumps 7.4%

    Kala Pharmaceuticals (KALA) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

  • Here's Why Kala Pharmaceuticals Fell as Much as 17.7% Today
    Motley Fool2 months ago

    Here's Why Kala Pharmaceuticals Fell as Much as 17.7% Today

    The pharma company announced the pricing of a share offering.

  • Business Wire3 months ago

    Kala Pharmaceuticals Announces Financing from Athyrium Capital Management Totaling $110 Million

    Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced the closing of Kala’s $110 million credit facility with funds managed by Athyrium Capital Management, LP, a leading healthcare focused investment firm. “We are pleased to be partnering with Athyrium and to have their support and confidence in INVELTYS for the treatment of inflammation and pain following ocular surgery and KPI-121 0.25% for dry eye disease,” said Mark Iwicki, Chairman, President and Chief Executive Officer of Kala Pharmaceuticals.

  • Business Wire3 months ago

    Kala Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Kala Pharmaceuticals, Inc. (“Kala”) (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, announced today that it has commenced an underwritten public offering of 7,500,000 shares of its common stock. Kala also intends to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,125,000 shares of common stock offered in the public offering at the public offering price, less the underwriting discount.

  • Is Kala Pharmaceuticals Inc’s (NASDAQ:KALA) Balance Sheet A Threat To Its Future?
    Simply Wall St.3 months ago

    Is Kala Pharmaceuticals Inc’s (NASDAQ:KALA) Balance Sheet A Threat To Its Future?

    Kala Pharmaceuticals Inc (NASDAQ:KALA) is a small-cap stock with a market capitalization of US$266.8m. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they Read More...

  • Business Wire3 months ago

    Kala Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Kala Pharmaceuticals, Inc. (KALA), a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 69,500 shares of Kala Pharmaceuticals common stock to seven new employees.

  • TheStreet.com3 months ago

    Six Biotechnology Names on My Watch List

    The indices have been slowly drifting lower after a gap up open. Early breadth was around 3 to 1 positive but its now down to around 4-3 positive. The bulls are not producing much positive momentum but the bears are doing an even worse job of producing negative momentum.

  • Business Wire4 months ago

    Kala Pharmaceuticals to Present at Upcoming Investor Conferences

    Kala Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating parti

  • Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA
    Zacks4 months ago

    Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA

    Regulatory and pipeline updates comprise some of the key developments in the biotech sector this week. These include Gilead's Yescarta approval in Europe.

  • Reuters4 months ago

    U.S. FDA approves Kala Pharma's eye pain drug

    The U.S. Food and Drug Administration on Thursday approved Kala Pharmaceuticals Inc's treatment for reducing inflammation and pain following an eye surgery. The company said it expects to launch the drug, Inveltys, in the beginning of 2019, with Wedbush Securities estimating peak sales of about $271 million in 2027. The drug was found to have no serious side effects during clinical trials, Kala said.

  • H.C. Wainwright Maintains Buy on Kala Pharmaceuticals (KALA) Ahead of Upcoming PDUFA Date
    SmarterAnalyst4 months ago

    H.C. Wainwright Maintains Buy on Kala Pharmaceuticals (KALA) Ahead of Upcoming PDUFA Date

    H.C. Wainwright analyst Ram Selvaraju is out this morning with another bullish note on shares of Kala Pharmaceuticals (NASDAQ:KALA), reiterating a Buy rating and price target of $35, which represents a potential upside of 197% from where the stock is currently trading. Selvaraju continues to see a favorable risk/reward profile on Kala heading into the August 24 PDUFA date for lead candidate, INVELTYS. If approved, INVELTYS would be the first FDA-approved corticosteroid eye drop with a twice daily dosing regimen for the treatment of post-operative ocular inflammation and pain. In our view, the combination of LE’s safety profile and dosing convenience should allow INVELTYS to seize market share from branded eye drops such as Lotemax and Durezol, as well as generic prednisolone.

  • Associated Press4 months ago

    Kala Pharma: 2Q Earnings Snapshot

    The Waltham, Massachusetts-based company said it had a loss of 60 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...

  • Business Wire4 months ago

    Kala Pharmaceuticals Reports Second Quarter 2018 Financial Results

    – PDUFA Target Action Date for INVELTYS™ is August 24, 2018 –